MedTrace Logo

A Microneurography Study of NaV1.8 Inhibition in Healthy Adults

NCT06420765 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 92

Last updated 2025-04-20

No results posted yet for this study

Summary

The purpose of this study is to determine the effects of Nav1.8 inhibition on activity-dependent slowing (ADS) of C-nociceptor nerve fibers, evoked action potential (AP) conduction velocity of C-nociceptor nerve fibers using VX-150, VX-993 and VX-548.

Conditions

Interventions

DRUG

VX-150

Suspension for oral administration.

DRUG

VX-548

Solution or suspension for oral administration.

DRUG

VX-993

Suspension for oral administration.

DRUG

Placebo

Suspension for oral administration.

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-05-21
Primary Completion
2025-03-22
Completion
2025-04-04
FDA Drug
Yes

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06420765 on ClinicalTrials.gov